Phlebodia 18's 600 mg film-coated tablets

The instruction for medical use of FLEBODIA 600 medicine the Trade name of Flebodia 600 International unlicensed names Diosmin Dosage Form of the Tablet, film coated, 600 mg Structure One tablet contains active agent - the diosmin purified (equivalent to diosmin anhydrous) 600 mg, excipients: microcrystalline cellulose, talc, silicon dioxide colloidal anhydrous, stearic acid, structure of a cover: protective film Sepifilmtm 002 (gipromelloza, cellulose microcrystalline, stearate makrogol 400), AP 5523 Sepisperstm dye pink (propylene glycol, gipromelloz, titan dioxide (E171), dye crimson
(E124), ferrous oxide red (E172), ferrous oxide black (E 172)), Opaglostm 6000 (wax palm, beeswax, gummilak, alcohol of 95%) Description of the Tablet of round shape, biconvex, film coated pink color. Pharmacotherapeutic group Vasoprotectives. The drugs reducing permeability of capillaries. Bioflavonoids. Diosmin. The ATX C05CA03 code the Pharmacological Pharmacokinetics Quickly properties is soaked up from digestive tract, it is found in blood plasma in 2 hours after reception. The maximum concentration in blood plasma is reached in 5 hours after reception. It is evenly distributed in all layers of a wall of venas cava and saphenas of the lower extremities, to a lesser extent – in kidneys, a liver, light and other fabrics. Selective accumulation of diosmin and/or its metabolites in venous vessels reaches a maximum by the 9th o'clock after reception and remains within 96 hours. It is removed with urine of 79%, with a stake – 11%, with bile - 2.4%. The pharmacodynamics Drug possesses flebotoniziruyushchy action: reduces extensibility of veins, raises a tone of veins (dose-dependent effect), reduces venous stagnation, improves a lymphatic drainage: raises a tone and frequency of reduction of lymphatic capillaries, increases their functional density, improves microcirculation: increases capillary resistance (dose-dependent effect), reduces their permeability, reduces adhesion of leukocytes to a venous wall and their migration in paravenous fabrics, improves diffusion of oxygen and perfusion in skin fabric, possesses anti-inflammatory action. Strengthens vasoconstrictive effect of adrenaline, noradrenaline, blocks development of free radicals, synthesis of prostaglandins and thromboxane. Indications - a varicosity of the lower extremities - chronic limfovenozny insufficiency of the lower extremities - pain and weight in legs (syndrome of heavy legs) - hemorrhoids - the increased fragility of capillaries, microcirculation disturbance the Route of administration and doses Inside. In a varicosity of the lower extremities and in an initial stage of chronic limfovenozny insufficiency (weight in legs) appoint on 1 tablet a day, in the morning till a breakfast. At chronic limfovenozny insufficiency (hypostases, pains, spasms, etc.) duration of a course of treatment is determined by the doctor depending on a course of the disease. In acute hemorrhoids appoint 2-3 tablets a day at meal time within 7 days. If you missed one or several receptions, continue use of drug in a usual dosage. Side effects Seldom - hypersensitivity to drug components - dispepsichesky disorders - a headache. The contraindication - individual intolerance - children's age up to 18 years Medicinal interactions of Clinically significant effects of interaction with other medicines is not described. Strengthening of vasoconstrictive effect of adrenaline and noradrenaline is possible. The special instructions Treatment of a Bad Attack of Hemorrhoids does not replace specific treatment of other anal diseases. In the absence of fast clinical effect it is necessary to perform additional examination and to correct the carried-out therapy. Presence of Ponso dye 4R (E124) can lead ment of allergic manifestations. Pregnancy and lactation are not established negative influences of drug on a course of pregnancy and fetation. Due to the insufficient experience of use of this drug during pregnancy, pregnant women are not recommended to apply. For the period of treatment it is necessary to refuse breastfeeding since there is not enough information on penetration of components of drug into breast milk. The feature of influence of drug on ability to run the vehicle or potentially dangerous mechanisms does not influence. Overdose Symptoms of overdose are not described. A form of release and packing On 15 or 18 tablets in planimetric cell packing from a film of polyvinylchloride and aluminum foil. On 1, 2 and 4 (on 15 tablets) or on 1 (on 18 tablets) blister strip packagings together with the instruction for medical use place in a cardboard pack. To Store storage conditions at a temperature not above 30 °C. To store out of children's reach! 3 years not to apply a period of storage after the expiration date specified on packing. Prescription status Without prescription the Producer Innotera Shuzi, Rue Rene Shantero, 41150, Shuzi-Sur-Cis, France. The owner of the registration certificate Innotera Laboratory, France the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products and responsible for post-registration observation of safety of medicine: Representation Innotek Internasional Laboratory of S.A.S. in RK 050059, Republic of Kazakhstan, Almaty, Al-Farabi Ave., 17, business center of Nurla Tau, block of 4 B, office 606, ph./fax: +7-727-311-09-71, +7-727-311-09-72, e-mail: innotech@innotech.kz